These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 27157244)

  • 1. Budesonide for the treatment of ulcerative colitis.
    Abdalla MI; Herfarth H
    Expert Opin Pharmacother; 2016 Aug; 17(11):1549-59. PubMed ID: 27157244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
    Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis.
    Bezzio C; Festa S; Zerboni G; Papi C; Manes G; Saibeni S
    Expert Opin Drug Saf; 2018 Apr; 17(4):437-444. PubMed ID: 29473429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis.
    Salice M; Rizzello F; Calabrese C; Privitera Hrustemovic H; Gionchetti P
    Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):607-613. PubMed ID: 31106602
    [No Abstract]   [Full Text] [Related]  

  • 5. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
    Danese S; Siegel CA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2014 May; 39(10):1095-103. PubMed ID: 24641622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical therapies in inflammatory bowel disease.
    Frei P; Biedermann L; Manser CN; Wilk M; Manz M; Vavricka SR; Rogler G
    Digestion; 2012; 86 Suppl 1():36-44. PubMed ID: 23051725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
    Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
    Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical therapy is underused in patients with ulcerative colitis.
    Seibold F; Fournier N; Beglinger C; Mottet C; Pittet V; Rogler G;
    J Crohns Colitis; 2014 Jan; 8(1):56-63. PubMed ID: 23566922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
    Gherardi A; Roze S; Kuijvenhoven J; Ghatnekar O; Yip Sonderegger YL
    J Med Econ; 2018 Sep; 21(9):869-877. PubMed ID: 29857775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
    Sandborn WJ; Travis S; Moro L; Jones R; Gautille T; Bagin R; Huang M; Yeung P; Ballard ED
    Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
    United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.
    Bezzio C; Fascì-Spurio F; Viganò C; Meucci G; Papi C; Saibeni S
    Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):33-41. PubMed ID: 27805459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM; Kushkuley S; Barrett JA; Oster G
    Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel extended release budesonide formulation for treatment of ulcerative colitis.
    Farkas K; Molnár T
    Expert Opin Pharmacother; 2014 Jan; 15(1):131-7. PubMed ID: 24219763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis.
    Hoy SM
    Drugs; 2015 May; 75(8):879-86. PubMed ID: 25920500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK; Irvine EJ
    Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budesonide multi-matrix system formulation for treating ulcerative colitis.
    Prantera C; Scribano ML
    Expert Opin Pharmacother; 2014 Apr; 15(6):741-3. PubMed ID: 24484392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD004115. PubMed ID: 20091560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of ulcerative colitis].
    Rammert Ch; Kullak-Ublick GA
    Ther Umsch; 2003 Mar; 60(3):145-50. PubMed ID: 12693317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
    Travis SP; Danese S; Kupcinskas L; Alexeeva O; D'Haens G; Gibson PR; Moro L; Jones R; Ballard ED; Masure J; Rossini M; Sandborn WJ
    Gut; 2014 Mar; 63(3):433-41. PubMed ID: 23436336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.